Results and exploratory biomarker analyses of a phase II study CHANGEABLE: combination of HX008 and niraparib in GErm-line-mutAted metastatic breast cancer
Background: The combination of poly (ADP-ribose) polymerase inhibitors and immune-checkpoint inhibitors demonstrated synergistic antitumor activity in preclinical studies. We aim to investigate the efficacy, safety, and biomarker analyses of the combination of niraparib and PD-1 inhibitor HX008 in m...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | The Lancet Regional Health. Western Pacific |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666606524003031 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|